High-flow nasal-cannula (HFNC) may be an oxygen modality useful for preventing invasive mechanical ventilation and mortality; however, its role in acute hypoxemic respiratory failure is not clearly defined. We sought to evaluate the impact of HFNC on mortality across immunocompromised subjects compared to alternative noninvasive oxygen therapies, namely conventional oxygen therapy and noninvasive ventilation (NIV).
METHODS:
We systematically searched the major databases to identify randomized, controlled trials (RCTs) or observational studies (until May 2018). We included studies reporting the use of HFNC in immunocompromised subjects and evaluated its impact on mortality and invasive mechanical ventilation.
RESULTS:
Upon review of 6,506 titles, 13 studies (1,956 subjects) fulfilled our inclusion criteria (4 RCTs, 9 observational studies). The predominant cause of immunocompromised status was cancer. Bacterial pneumonia was the most common cause of acute hypoxemic respiratory failure with a median PaO2/FIO2 of 145 mm Hg (interquartile range 115–175). HFNC was used as the first oxygen strategy in 474 subjects compared to NIV (242 subjects) and conventional O2 therapy (703 subjects). There was a 46% rate of invasive mechanical ventilation and 36% mortality. Mortality at the longest available follow-up was lower with HFNC compared to the oxygen therapy controls (NIV or conventional O2 therapy) in 7 studies (1,429 subjects; relative risk 0.72, 95% CI 0.56–0.93, P = .01). There was a lower rate of invasive mechanical ventilation with HFNC compared to the oxygen therapy controls across 8 studies (1,529 subjects, relative risk 0.81, 95% CI 0.67–0.96, P = .02). These results were robust across a series of sensitivity analyses.
CONCLUSIONS:
There exists a need to develop a greater evidence base evaluating the utility of HFNC in immunocompromised subjects. In our exploratory analysis, HFNC was found to decrease mortality and use of invasive mechanical ventilation compared to alternative noninvasive oxygen controls. These results are meant to be exploratory. Higher-quality studies evaluating a more homogeneous population are needed to further elucidate its benefit.
AzoulayE, MokartD, PeneF, LambertJ, KouatchetA, MayauxJ, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium–a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol, 2013; 31(22):2810–2818.
2.
AzevedoLCP, CarusoP, SilvaUVA, TorellyAP, SilvaE, RezendeE, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest, 2014; 146(2):257–266.
3.
AddaM, CoquetI, DarmonM, ThieryG, SchlemmerB, AzoulayE. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med, 2008; 36(10):2766–2772.
4.
MolinaR, BernalT, BorgesM, ZaragozaR, BonastreJ, GranadaRM, et al. Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care, 2012; 16(4):R133.
5.
AzoulayE, LemialeV, MokartD, PeneF, KouatchetA, PerezP, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med, 2014; 40(8):1106–1114.
6.
HilbertG, GrusonD, VargasF, ValentinoR, Gbikpi-BenissanG, DuponM, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med, 2001; 344(7):481–487.
7.
AntonelliM, ContiG, BufiM, CostaMG, LappaA, RoccoM, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. JAMA, 2000; 283(2):235–241.
8.
LemialeV, MokartD, Resche-RigonM, PeneF, MayauxJ, FaucherE, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA, 2015; 314(16):1711–1719.
9.
LiuJ, BellC, CampbellV, DeBackerJ, TambergE, LeeC, et al. Noninvasive ventilation in patients with hematologic malignancy. J Intensive Care Med, 2017 [Epub ahead of print] doi: 10.1177/0885066617690725.
10.
HuangHB, XuB, LiuGY, LinJD, DuB. Use of noninvasive ventilation in immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis. Crit Care, 2017; 21(1):4.
11.
WangT, ZhangL, LuoK, HeJ, MaY, LiZ, et al. Noninvasive versus invasive mechanical ventilation for immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis. BMC Pulm Med, 2016; 16(1):129.
12.
FratJP, ThilleAW, MercatA, GiraultC, RagotS, PerbetS, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med, 2015; 372(23):2185–2196.
13.
NiYN, LuoJ, YuH, LiuD, NiZ, ChengJ, et al. Can high-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation? A systematic review and meta-analysis. Chest, 2017; 151(4):764–775.
14.
StephanF, BarrucandB, PetitP, Rezaiguia-DelclauxS, MedardA, DelannoyB, et al. High-flow nasal oxygen vs noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery: a randomized clinical trial. JAMA, 2015; 313(23):2331–2339.
15.
NishimuraM. High-flow nasal cannula oxygen therapy in adults. J Intensive Care, 2015; 3(1):15.
16.
NishimuraM. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care, 2016; 61(4):529–541.
17.
HigginsJP, AltmanDG, GotzschePC, JuniP, MoherD, OxmanAD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011; 343:d5928.
18.
WellsG, SheaB, O'ConnellD, PetersonJ, WelchV, LososM, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2009.
19.
DerSimonianR, LairdN. Meta-analysis in clinical trials. Control Clin Trials, 1986; 7(3):177–188.
AzoulayE, PickkersP, SoaresM, PernerA, RelloJ, BauerPR, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med, 2017; 43(12):1808–1819.
22.
LeeHY, RheeCK, LeeJW. Feasibility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematologic malignancies: a retrospective single-center study. J Crit Care, 2015; 30(4):773–777.
23.
DureyA, KangS, SuhYJ, HanSB, KimAJ. Application of high-flow nasal cannula to heterogeneous condition in the emergency department. Am J Emerg Med, 2017; 35(8):1199–1201.
24.
TuG, HeH, YinK, JuM, ZhengY, ZhuD, et al. High-flow nasal cannula versus noninvasive ventilation for treatment of acute hypoxemic respiratory failure in renal transplant recipients. Transplant Proc, 2017; 49(6):1325–1330.
25.
HuiD, MorgadoM, ChisholmG, WithersL, NguyenQ, FinchC, et al. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial. J Pain Symptom Manage, 2013; 46(4):463–473.
26.
LemialeV, MokartD, MayauxJ, LambertJ, RabbatA, DemouleA, et al. The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial. Crit Care, 2015; 19:380.
27.
CoudroyR, JametA, PetuaP, RobertR, FratJP, ThilleAW. High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study. Ann Intensive Care, 2016; 6(1):45.
28.
FratJP, RagotS, GiraultC, PerbetS, PratG, BoulainT, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med, 2016; 4(8):646–652.
29.
LemialeV, Resche-RigonM, MokartD, PeneF, ArgaudL, MayauxJ, et al. High-flow nasal cannula oxygenation in immunocompromised patients with acute hypoxemic respiratory failure: a groupe de recherche respiratoire en reanimation onco-hematologique study. Crit Care Med, 2017; 45(3):e274–e280.
30.
HaradaK, KurosawaS, HinoY, YamamotoK, SakaguchiM, IkegawaS, et al. Clinical utility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematological disease. Springerplus, 2016; 5:512.
31.
MokartD, GeayC, Chow-ChineL, BrunJP, FaucherM, BlacheJL, et al. High-flow oxygen therapy in cancer patients with acute respiratory failure. Intensive Care Med, 2015; 41(11):2008–2010.
32.
RocaO, de AciluMG, CaraltB, SacanellJ, MasclansJR. Humidified high flow nasal cannula supportive therapy improves outcomes in lung transplant recipients readmitted to the intensive care unit because of acute respiratory failure. Transplantation, 2015; 99(5):1092–1098.
33.
KimWY, SungH, HongSB, LimCM, KohY, HuhJW. Predictors of high flow nasal cannula failure in immunocompromised patients with acute respiratory failure due to non-HIV pneumocystis pneumonia. J Thorac Dis, 2017; 9(9):3013–3022.
34.
MaitraS, SomA, BhattacharjeeS, AroraMK, BaidyaDK. Comparison of high-flow nasal oxygen therapy with conventional oxygen therapy and noninvasive ventilation in adult patients with acute hypoxemic respiratory failure: A meta-analysis and systematic review. J Crit Care, 2016; 35:138–144.
35.
LieschingTN, LeiY. Efficacy of high-flow nasal cannula therapy in intensive care units. J Intensive Care Med, 2017 [Epub ahead of print] doi: 10.1177/0885066616689043.
36.
BrowerRG, MatthayMA, MorrisA, SchoenfeldD, ThompsonBT, WheelerA. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000; 342(18):1301–1308.
37.
BrochardL. Ventilation-induced lung injury exists in spontaneously breathing patients with acute respiratory failure: yes. Intensive Care Med, 2017; 43(2):250–252.
38.
AmatoMB, MeadeMO, SlutskyAS, BrochardL, CostaEL, SchoenfeldDA, et al. Driving pressure and survival in the acute respiratory distress syndrome. New Engl J Med, 2015; 372(8):747–755.
39.
EstebanA, Frutos-VivarF, FergusonND, ArabiY, ApezteguiaC, GonzalezM, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med, 2004; 350(24):2452–2460.
40.
GoldsteinRA, RohatgiPK, BergofskyEH, BlockER, DanieleRP, DantzkerDR, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis, 1990; 142(2):481–486.
41.
PatelBK, WolfeKS, PohlmanAS, HallJB, KressJP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA, 2016; 315(22):2435–2441.
